The Ophthalmic drug delivery therapeutics for retinal disorders
Delivery of therapeutics to the human eye is among the most interesting endeavours a formulator can take on, but also one of the most challenging. The anatomy and chemical make-up of the eye make it highly resistant to therapeutic penetration. Successfully circumventing these protective barriers requires intimate knowledge of the constraints of ophthalmic delivery as well as specialized formulation and development expertise. According to WHO, Drug delivery to the eye in particular is expected to experience the largest growth in the next five years and 55% of debilitating ocular diseases affect this segment. The global cost of vision loss is nearly US$3 billion which is approximately 2.1 billion euros.
The purpose of this whitepaper is to give an overall scenario of the different types of ophthalmic drug delivery system covering both the anterior and posterior regions of the eye, the present and future developments taking place in the ophthalmic drug delivery system, the clinical trial scenario of the emerging ophthalmic drug delivery systems and a look into the recent advancements coming in the ophthalmic drug delivery market.
Through this whitepaper, DelveInsight has highlighted an overview of the Ocular drug delivery market by showcasing the developments, key strategies and players, and key global market scenario.